New report
Diagnostics Partnering Terms and Agreements
charlottebritton : January 24, 2012 11:20 AM : Featured, Reports, Technology reportsThe Diagnostics Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading healthcare companies. more »
Latest partnering news
Roche enters strategic alliance with Technoclone
January 27, 2012 : Big Pharma, partnering, Roche
Roche has entered into a strategic alliance with Technoclone, a reagent specialist in thrombosis and cardiovascular diagnostics to co-develop a complete range of coagulation assays. more »
Santhera and Ipsen renegotiate fipamezole licensing agreement
January 25, 2012 : partnering
Santhera Pharmaceuticals have renegotiated their fipamezole licensing agreement.
Santhera regains the worldwide rights to the development and commercialization of fipamezole, its first-in-class selective adrenergic alpha-2 receptor antagonist for the management of levodopa-induced Dyskinesia in Parkinson’s Disease. more »
Latest M&A news
Celgene to acquire Avila Therapeutics
January 27, 2012 : Big Pharma
Celgene Corporation and Avila Therapeutics have announced a definitive merger agreement under which Celgene Corporation will acquire Avila Therapeutics. more »
Amgen to acquire Micromet for $1.16 billion
January 27, 2012 : Amgen, Big Pharma, M&A
Amgen and Micromet have entered into a definitive merger agreement under which Amgen will acquire Micromet for $11 per share in cash.
The transaction, which values Micromet at approximately $1.16 billion, was unanimously approved by both the Amgen and Micromet Boards of Directors. more »
Latest financing news
Verastem announces pricing of initial public offering
January 27, 2012 : financings
Verastem announced the pricing of its initial public offering of 5,500,000 shares of its common stock at $10.00 per share, before underwriting discounts and commissions.
All of the shares in the offering are being sold by Verastem. more »
ProSensa raises €23 million in equity sale
January 25, 2012 : financings
Prosensa has raised €23 million in new equity financing.
The financing was led by new investor New Enterprise Associates (NEA) and was supported by existing Prosensa investors, Abingworth, Life Sciences Partners, Gimv, Idinvest Partners and MedSciences Capital. more »
Latest Dealtalk
Abbott Labs slips as Q4 sales come in below estimates
January 26, 2012 : Abbott, Big Pharma, dealtalk
Written by Alex Nussbaum for Bloomberg.
Abbott Laboratories, the health-care company that plans to spin off its drug business, fell the most in two months after reporting fourth-quarter sales that came in below analyst estimates. more »
Trivitron Healthcare eyes $100 million PE funding
January 24, 2012 : dealtalk, financings
Medical device maker Trivitron Healthcare is looking for private equity funding to the tune of $100 million. “We will start talking to potential investors in February/March and close the deal in three months,” said Mr G.S.K. Velu, Founder and Managing Director, Trivitron, which is eyeing top private equity investors globally. more »
Featured reports
Biomarker Partnering Terms & Agreements
Publication date: February 2012
Diagnostics Partnering Terms and Agreements
Publication date: February 2012
Partnering Yearbook 2012
Publication date: January 2012
Recent insights
Dealmakers weekly review – January 23 2012 – Genentech, Paragon Bioservices, Neurocrine Biosciences
January 23, 2012
Biotech funding hits 4-year high as startups suffer
January 23, 2012
Points of view
Avila Therapeutics to be acquired by Celgene for $925 million
January 27, 2012
Amgen buys Micromet for $1.2 billion gaining leukemia drug and R&D center of excellence
January 27, 2012
Scorecard
Current Partnering provides access to key deal metrics for all leading partnering, M&A and financings - plus big pharma partnering activity and R&D spend metrics.
Available scorecards:
